Switch theme
Sign up to access all valuation multiples
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
2002
5
LTM Revenue $1.2M
LTM EBITDA -$1.5M
$19.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pharma Equity Group has a last 12-month revenue (LTM) of $1.2M and a last 12-month EBITDA of -$1.5M.
In the most recent fiscal year, Pharma Equity Group achieved revenue of n/a and an EBITDA of -$3.2M.
Pharma Equity Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharma Equity Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | -$1.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | -117% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$1.5M | XXX | -$3.2M | XXX | XXX | XXX |
| EBITDA Margin | -129% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$2.0M | XXX | -$3.2M | XXX | XXX | XXX |
| EBIT Margin | -170% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$2.4M | XXX | -$3.7M | XXX | XXX | XXX |
| Net Margin | -207% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pharma Equity Group's stock price is DKK 0 (or $0).
Pharma Equity Group has current market cap of DKK 119M (or $17.9M), and EV of DKK 128M (or $19.3M).
See Pharma Equity Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.3M | $17.9M | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pharma Equity Group has market cap of $17.9M and EV of $19.3M.
Pharma Equity Group's trades at n/a EV/Revenue multiple, and -6.1x EV/EBITDA.
Equity research analysts estimate Pharma Equity Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharma Equity Group has a P/E ratio of -7.5x.
See valuation multiples for Pharma Equity Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.9M | XXX | $17.9M | XXX | XXX | XXX |
| EV (current) | $19.3M | XXX | $19.3M | XXX | XXX | XXX |
| EV/Revenue | 16.7x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -13.0x | XXX | -6.1x | XXX | XXX | XXX |
| EV/EBIT | -9.8x | XXX | -6.0x | XXX | XXX | XXX |
| EV/Gross Profit | -14.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.5x | XXX | -4.9x | XXX | XXX | XXX |
| EV/FCF | -8.2x | XXX | -5.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharma Equity Group's last 12 month revenue growth is 254%
Pharma Equity Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.6M for the same period.
Pharma Equity Group's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharma Equity Group's rule of X is 507% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pharma Equity Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 254% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -129% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -265% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 507% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharma Equity Group acquired XXX companies to date.
Last acquisition by Pharma Equity Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharma Equity Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pharma Equity Group founded? | Pharma Equity Group was founded in 2002. |
| Where is Pharma Equity Group headquartered? | Pharma Equity Group is headquartered in Denmark. |
| How many employees does Pharma Equity Group have? | As of today, Pharma Equity Group has 5 employees. |
| Is Pharma Equity Group publicy listed? | Yes, Pharma Equity Group is a public company listed on CSE. |
| What is the stock symbol of Pharma Equity Group? | Pharma Equity Group trades under PEG ticker. |
| When did Pharma Equity Group go public? | Pharma Equity Group went public in 2003. |
| Who are competitors of Pharma Equity Group? | Similar companies to Pharma Equity Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pharma Equity Group? | Pharma Equity Group's current market cap is $17.9M |
| What is the current revenue of Pharma Equity Group? | Pharma Equity Group's last 12 months revenue is $1.2M. |
| What is the current revenue growth of Pharma Equity Group? | Pharma Equity Group revenue growth (NTM/LTM) is 254%. |
| What is the current EV/Revenue multiple of Pharma Equity Group? | Current revenue multiple of Pharma Equity Group is 16.7x. |
| Is Pharma Equity Group profitable? | Yes, Pharma Equity Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pharma Equity Group? | Pharma Equity Group's last 12 months EBITDA is -$1.5M. |
| What is Pharma Equity Group's EBITDA margin? | Pharma Equity Group's last 12 months EBITDA margin is -129%. |
| What is the current EV/EBITDA multiple of Pharma Equity Group? | Current EBITDA multiple of Pharma Equity Group is -13.0x. |
| What is the current FCF of Pharma Equity Group? | Pharma Equity Group's last 12 months FCF is -$2.3M. |
| What is Pharma Equity Group's FCF margin? | Pharma Equity Group's last 12 months FCF margin is -203%. |
| What is the current EV/FCF multiple of Pharma Equity Group? | Current FCF multiple of Pharma Equity Group is -8.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
